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Pulmonary arterial hypertension (PAH) is a fatal disease characterized by enhanced proliferation and 
reduced apoptosis of pulmonary arterial smooth muscle cells (PASMCs).  Here, we target 
hyperproliferative feature of PASMC in patients with PAH to discover a novel drug that inhibits its 
proliferation.  To discover a novel compound for PAH patients from the original 5,562 compounds, we 
performed stepwise screenings for 5,562 compounds from original library.  In the first screening, we 
performed MTT assay for each compound (5 μM/L) and found 80 compounds that effectively inhibited 
proliferation compared with controls (>20%).  In the second screening, we performed the repeatability 
assay and the counter assay to exclude the compounds with cell toxicity.  In the third screening, we 
performed a concentration-dependent assay and finally found that emetine inhibits PAH-PASMCs 
proliferation without any toxicity in normal PASMCs.  Interestingly, emetine significantly reduced 
protein levels of hypoxia-inducible factors (HIF-1α and HIF-2α) and downstream pyruvate 
dehydrogenase kinase 1.  Moreover, emetine significantly reduced the protein levels of RhoA, 
Rho-kinase (ROCK1 and ROCK2), and their downstream cyclophilin A and basigin in PAH-PASMCs.  
Consistently, emetine treatment significantly reduced the secretion of cytokines/chemokines and growth 
factors from PAH-PASMCs.  Next, we performed functional tests for emetine in vivo.  Six-week-old 
male SD rats were used for the two experimental PH models; monocrotaline-induced PH model and 
SU5416/hypoxia-induced PH model.  Importantly, emetine treatment as 0.05 mg/kg/day which is twenty 
times much lower than clinical dose in human ameliorated pulmonary hypertension in two experimental 
rat models by reducing right ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH), 
and pulmonary artery (PA) remodeling compared with vehicle controls. Moreover, emetine treatment 
reduced inflammatory cytokines/chemokines and growth factors in serum compared with vehicles 
controls.  Finally, emetine treatment improved RV functions and enhanced exercise capacity compared 
with vehicle controls.  In conclusion, by using high-throughput screening, we identified emetine that 
reduces excessive proliferation of PAH-PASMCs and ameliorates pulmonary arterial hypertension, is a 
natural alkaloid extracted from Psychotria ipecacuanha, which has been traditionally used to treat cough 
and amebiasis. 
